Novel approaches to identification of biomarkers for detection of early stage cancer

Disease Markers

Volumn 18, Issue 2, 2002, Pages 73-81

  Kiviat, Nancy B ^a   Critchlow, Cathy W ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cancer biomarkers; Early cancer detection; Genomic based screening

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

ARTICLE; ASSAY; CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER GENETICS; CANCER LOCALIZATION; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CARCINOMA IN SITU; EARLY CANCER; EARLY DIAGNOSIS; HUMAN; OVARY; PANCREAS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TECHNOLOGY;

EID: 0036399643     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2002/589075     Document Type: Article

References (85)

1. M.P. Achary, W. Jaggernauth, E. Gross, A. Alfieri, H.P. Klinger and B. Vikram, Cell lines from the same cervical carcinoma but with different radiosensitivities exhibit different cDNA microarray patterns of gene expression, Cytogenet Cell Genet 91 (2000), 39-43.
2. S.A. Belinsky, K.J. Nikula, W.A. Palmisano, R. Michels, G. Saccomanno, E. Gabrielson, S.B. Baylin and J.G. Herman, Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis, Proc Natl Acad Sci USA 95 (1998), 11891-11896.
3. L. Bermont, M.P. Algros, M.H. Baron and G.L. Adessi, Relevance of p185 HER-2/neu oncoprotein quantification in human primary breast carcinoma, Breast Cancer Res Treat 63 (2000), 163-169.
4. M.J. Birrer, D. Hendricks, J. Farley, M.J. Sundborg, T. Bonome, M.J. Walts and J. Geradts, Abnormal FHIT expression in malignant and premalignant lesions of the cervix, Cancer Res 59 (1999), 5270-5274.
5. J.O. Bishop, J.G. Morton, M. Rosbash and M. Richardson, Three abundance classes in HeLa cell messenger RNA, Nature 250 (1974), 199-204.
6. J.D. Brenton, S.A. Aparicio and C. Caldas, Molecular profiling of breast cancer: portraits but not physiognomy, Breast Cancer Res 3 (2001), 77-80.
7. D. Butler, C. Collins, M. Mabruk, C. Barry Walsh, M.B. Leader and E.W. Kay, Deletion of the FHIT gene in neoplastic and invasive cervical lesions is related to high-risk HPV infection but is independent of histopathological features, J Pathol 192 (2000), 502-510.
8. J.E. Celis, H.H. Rasmussen, H. Vorum, P. Madsen, B. Honore, H. Wolf and T.F. Orntoft, Bladder squamous cell carcinomas express psoriasin and externalize it to the urine, J Urol 155 (1996), 2105-2112.
9. K.C. Cheng and L.A. Loeb, Genomic stability and instability: a working paradigm, Curr Top Microbiol Immunol 221 (1997), 5-18.
10. P.A. Clarke, I. Hostein, U. Banerji, F.D. Stefano, A. Maloney, M. Walton, I. Judson and P. Workman, Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone, Oncogene 19 (2000), 4125-4133.
11. G.M. Cooper, Oncogenes, Jones and Barlett, Boston, 1995.
12. J.F. Costello, M.C. Fruhwald, D.J. Smiraglia, L.J. Rush, G.P. Robertson, X. Gao, F.A. Wright, J.D. Feramisco, P. Peltomaki, J.C. Lang, D.E. Schuller, L. Yu, C.D. Bloomfield, M.A. Caligiuri, A. Yates, R. Nishikawa, H. Su Huang, N.J. Petrelli, X. Zhang, M.S. O'Dorisio, W.A. Held, W.K. Cavenee and C. Plass, Aberrant CpG-island methylation has non-random and tumour-type-specific patterns, Nat Genet 24(2) (2000), 132-138.
13. J. DeRisi, L. Penland, P.O. Brown, M.L. Bittner, P.S. Meltzer, M. Ray, Y. Chen, Y.A. Su and J.M. Trent, Use of a cDNA microarray to analyse gene expression patterns in human cancer, Nat Genet 14 (1996), 457-460.
14. M. Esteller, L. Catasus, X. Matias-Guiu, G.L. Mutter, J. Prat, S.B. Baylin and J.G. Herman, hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis, Am J Pathol 155(5) (1999), 1767-1772.
15. M. Esteller, P.G. Corn, S.B. Baylin and J.G. Herman, A gene hypermethylation profile of human cancer, Cancer Res 61(8) (2001), 3225-3229.
16. M. Esteller, M. Sanchez-Cespedes, R. Rosell, D. Sidransky, S.B. Baylin and J.G. Herman, Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients, Cancer Res 59 (1999), 67-70.
17. M. Esteller, A. Sparks, M. Toyota, M. Sanchez-Cespedes, G. Capella, M.A. Peinado, S. Gonzalez, G. Tarafa, D. Sidransky, S.J. Meltzer, S.B. Baylin and J.G. Herman, Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer, Cancer Res 60(16) (2000), 4366-4371.
18. M. Esteller, M. Toyota, M. Sanchez-Cespedes, G. Capella, M.A. Peinado, D.N. Watkins, J.P. Issa, D. Sidransky, S.B. Baylin and J.G. Herman, Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis, Cancer Res 60(9) (2000), 2368-2371.
19. J.A. Figueroa, S. De Raad, V.O. Speights and J.J. Rinehart, Gene expression of insulin-like growth factors and receptors in neoplastic prostate tissues: correlation with clinicopathological parameters, Cancer Invest 19 (2001), 28-34.
20. F. Forozan, E.H. Mahlamaki, O. Monni, Y. Chen, R. Veldman, Y. Jiang, G.C. Gooden, S.P. Ethier, A. Kallioniemi and O.P. Kallioniemi, Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data, Cancer Res 60 (2000), 4519-4525.
21. M. Frommer, L.E. McDonald, D.S. Millar, C.M. Collis, F. Watt, G.W. Grigg, P.L. Molloy and C.I. Paul, A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands, Proc Natl Acad Sci 89 (1992), 1827-1831.
22. Y. Fu, Detection of differentially expressed genes in cancer using differential display, Methods Mol Med 68 (2002), 179-193.
23. R.S. Gitan, S. Huidong, C.M. Chen, P.S. Yan and T.H. Huang, Methylation-specific oligonucleotide microarray: A new potential for high-throughput methylation analysis, Genome Res 12 (2001), 158-164.
24. D.L. Greenspan, D.C. Connolly, R. Wu, R.Y. Lei, J.T. Vogelstein, Y.T. Kim, J.E. Mok, N. Munoz, F.X. Bosch, K. Shah and K.R. Cho, Loss of FHIT expression in cervical carcinoma cell lines and primary tumors, Clin Cancer Res 57(21) (1997), 4692-4698.
25. A.K. Gregorakis, E.H. Holmes and G.P. Murphy, Prostate-specific membrane antigen: current and future utility, Semin Urol Oncol 16(1) (1998), 2-12.
26. T.J. Griffin and L.M. Smith, Single-nucleotide polymorphism analysis by MALDI-TOF mass spectrometry, Trends Biotechnol 18(2) (2000, 77-84.
27. Y. Hayashizaki, S. Hirotsune, Y. Okazaki, I. Hatada, H. Shibata, J. Kawai, K. Hirose, S. Watanabe, S. Fushiki and S. Wada et al., Restriction landmark genomic scanning method and its various applications, Electrophoresis 14(4) (1993), 251-258.
28. I. Hedenfalk, D. Duggan, Y. Chen, M. Radmacher, M. Bittner, R. Simon, P. Meltzer, B. Gusterson, M. Esteller, O.P. Kallioniemi, B. Wilfond, A. Borg and J. Trent, Gene-expression profiles in hereditary breast cancer, N Engl J Med 344 (2001), 539-548.
29. T.M. Hong, P.C. Yang, K. Peck, J.J. Chen, S.C. Yang, Y.C. Chen and C.W. Wu, Profiling the downstream genes of tumor suppressor PTEN in lung cancer cells by complementary DNA microarray, Am J Respir Cell Mol Biol 23 (2000), 355-363.
30. http://www.genetics.nature.com/web_specials/, The chipping forecast, Nature Genetics 21 (1998), 1-60.
31. X. Hu, Z. Guo, T. Pang, Q. Li, G. Afink and J. Ponten, Immunohistochemical and DNA sequencing analysis on human mismatch repair gene MLH1 in cervical squamous cell carcinoma with LOH of this gene, Anticancer Res 20 (2000), 171-175.
32. G.M. Huang, W.L. Ng, J. Farkas, L. He, H.A. Liang, D. Gordon, J. Yu and L. Hood, Prostate cancer expression profiling by cDNA sequencing analysis, Genomics 59 (1999), 178-186.
33. T.H. Huang, M.R. Perry ADN D.E. Laux, Methylation profiling of CpG islands in human breast cancer cells, Hum Mol Genet 8(3) (1999), 459-470.
34. A.L. Jackson and L.A. Loeb, On the origin of multiple mutations in human cancers, Semin Cancer Biol 8(6) (1998), 421-429.
35. K.K. Jain, Proteomics: new technologies and their applications, Drug Discov Today 6(9) (2001), 457-459.
36. L.A. James, Comparative genomic hybridiazation as a tool in tour cytogenetics, J Pathol 87 (1999), 385-395.
37. R. Kandel, X.L. Zhu, S.Q. Li and T. Rohan, Cyclin D1 protein overexpression and gene amplification in benign breast tissue and breast cancer risk, Eur J Cancer Prev 10 (2001), 43-51.
38. J. Khosravi, A. Diamandi, J. Mistry and A. Scorilas, Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer, J Clin Endocrinol Metab 86 (2001), 694-699.
39. C.L. Kosary, L.A.G. Ries, B.A. Miller, B.F. Hankey, A. Harras and B.K. Edwards, eds, SEER Cancer Statistics Review, 1973-1992: Tables and Graphs, National Cancer Institute. NIH Pub. No. 96-2789, Bethesda, MD, 1995.
40. J.J. Kurebayashi, Biological and clinical significance of HER2 overexpression in breast cancer, Breast Cancer 8 (2001), 45-51.
41. L.C. Lawrie, J.E. Fothergill and G.I. Murray, Spot the differences: proteomics in cancer research, Lancet Oncol 2(5) (2001), 270-277.
42. G. Liang, C.E. Salem, M.C. Yu, H.D. Nguyen, F.A. Gonzales, T.T. Nguyen, P.W. Nichols and P.A. Jones, DNA methylation differences associated with tumor tissues identified by genome scanning analysis, Genomics 53(3) (1998), 260-268.
43. D.J. Liao and R.B. Dickson, c-Myc in breast cancer, Endocr Relat Cancer 7 (2000), 143-164.
44. D.J. Liao, G. Natarajan, S.L. Deming, M.H. Jamerson, M. Johnson, G. Chepko and R.B. Dickson, Cell cycle basis for the onset and progression of c-Myc-induced, TGFalpha-enhanced mouse mammary gland carcinogenesis, Oncogene 19 (2000), 1307-1317.
45. K.O. Lloyd, Humoral immune responses to tumor-associated carbohydrate antigens, Semin Cancer Biol 2(6) (1991), 421-431.
46. D.B. Martin and P.S. Nelson, From genomics to proteomics: techniques and applications in cancer research, Trends Cell Biol 11(11) (2001), S60-65.
47. M.V. Matz and S.A. Lukyanov, Different strategies of differential display: areas of application, Nucleic Acids Research 26 (24) (1998), 5537-5543.
48. M. Merchant and S.R. Weinberger, Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry, Electrophoresis 21(6) (2000), 1164-1177.
49. P.S. Nelson, L. Gan, C. Ferguson, P. Moss, R. Gelinas, L. Hood and K. Wang, Molecular cloning and characterization of prostase, an androgen- regulated serine protease with prostate-restricted expression, Proc Natl Acad Sci USA 96 (1999), 3114-3119.
50. P.S. Nelson, D. Han, Y. Rochon, G.L. Corthals, B. Lin, A. Monson, V. Nguyen, B.R. Franza, S.R. Plymate, R. Aebersold and L. Hood, Comprehensive analyses of prostate gene expression: convergence of expressed sequence tag databases, transcript profiling and proteomics, Electrophoresis 21(9) (2000), 1823-1831.
51. P.S. Nelson, W.L. Ng, M. Schummer, L.D. True, A.Y. Liu, R.E. Bumgarner, C. Ferguson, A. Dimak and L. Hood, An expressed-sequence-tag database of the human prostate: sequence analysis of 1168 cDNA clones, Genomics 47 (1998), 12-25.
52. R.W. Nelson, The use of bioreactive probes in protein characterization, Mass Spectrom Rev 16(6) (1997), 353-376.
53. W.-L. Ng, M. Schummer, F. Cirisano, R.L. Baldwin, B.Y. Karlan and L. Hood, High-throughput plasmid minipreparations facilitated by micro-mixing, Nucl Acids Res 24 (1996), 5045-5047.
54. Y.L. Oh, J.S. Choi, S.Y. Song, Y.H. Ko, B.K. Han, S.J. Nam and J.H. Yang, Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status, Pathol Int 51 (2001), 94-99.
55. L.J. Old, Cancer immunology: the search for specificity. G.H.A. Lowes Memorial Lecture, Cancer Res 41 (1981), 361-375.
56. L.J. Old and Y.T. Chen, New paths in human cancer serology, J Exp Med 187 (1998), 1163-1167.
57. K. Ono, T. Tanaka, T. Tsunoda, O. Kitahara, C. Kihara, A. Okamoto, K. Ochiai, T. Takagi and Y. Nakamura, Identification by cDNA microarray of genes involved in ovarian carcinogenesis, Cancer Res 60 (2000), 5007-5011.
58. W.A. Palmisano, K.K. Divine, G. Saccomanno, F.D. Gilliland, S.B. Baylin, J.G. Herman and S.A. Belinsky, Predicting lung cancer by detecting aberrant promoter methylation in sputum, Cancer Res 60(21) (2000), 5954-5958.
59. S.D. Patterson, Mass spectrometry and proteomics, Physiol Genomics 2(2) (2000), 59-65.
60. S. Petersen, C. Heckert, J. Rudolf, K. Schluns, O.I. Tchernitsa, R. Schafer, M. Dietel and I. Petersen, Gene expression profiling of advanced lung cancer, Int J Cancer 86 (2000), 512-517.
61. R. Peto, Epidemiology, multistage models and short-stage mutagenicity tests, in: Origins of Human Cancer, H.H. Hiatt, J.D. Watson and J.A. Winsten, eds, Cold Spring Harbor Laboratory, New York, 1977, pp. 1403-1428.
62. J. Preiherr, T. Hildebrandt, S. Klostermann, S. Eberhardt, S. Kaul and U.H. Weidle, Transcriptional profiling of human mammary carcinoma cell lines reveals PKW, a new tumor-specific gene, Anticancer Res 20 (2000), 2255-2264.
63. A.K. Raap, Advances in fluorescence in situ hybridization, Mutat Res 400 (1998), 287-298.
64. M.R. Rebagliati, D.L. Weeks, R.P. Harvey and D.A. Melton, Identification and cloning of localized maternal RNAs from Xenopus eggs, Cell 42 (1985), 769-777.
65. R. Roylance, Methods of molecular analysis: assessing losses and gains in tumours, Mole Path 55(1) (2002), 25-28.
66. U. Sahin, O. Tureci, H. Schmitt, B. Cochlovius, T. Hohannes, R. Schmits, F. Stenner, G. Lou, I. Schobert and M. Pfeereundschuh, Human neoplasms elicit multiple imune responses in the autologous host, Proc Natl Acad Sci USA 92 (1995), 11810-11813.
67. M.J. Scanlan, Y.T. Chen, B. Williamson, A.O. Gure, E. Stockert, J.D. Gordan, O. Tureci, U. Sahin, M. Pfreundschuh and L.J. Old, Characterization of human colon cancer antigens recognized by autologous antibodies, Int J Cancer 76 (1998), 652-658.
68. M. Scherl-Mostageer, W. Sommergruber, R. Abseher, R. Hauptmann, P. Ambros and N. Schweifer, Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer, Oncogene 20(32) (2001), 4402-4408.
69. M. Schummer, W.V. Ng, R.E. Bumgarner, P.S. Nelson, B. Schummer, D.W. Bednarski, L. Hassell, R.L. Baldwin, B.Y. Karlan and L. Hood, Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas, Gene 238(2) (1999), 375-385.
70. D.C. Sgroi, S. Teng, G. Robinson, R. LeVangie, J.R. Hudson and A.G. Elkahloun, In vivo gene expression profile analysis of human breast cancer progression, Cancer Res 59 (1999), 5656-5661.
71. J.E. Sokal and G.A. Gomez, The Philadelphia chromosome and Philadelphia chromosome mosaicism in chronic granulocytic leukemia, J Clin Oncol 4(1) (1986), 104-111.
72. S. Takeo, H. Arai, N. Kusano, T. Harada, T. Furuya, S. Kawauchi, A. Oga, T. Hirano, T. Yoshida, K. Okita and K. Sasaki, Examination of oncogene amplification by genomic DNA microarray in hepatocellular carcinomas: comparison with comparative genomic hybridization analysis, Cancer Genet Cytogenet 130(2) (2001), 127-132.
73. R. Theberge, L.H. Connors, M. Skinner and C.E. Costello, Detection of transthyretin variants using immunoprecipitation and matrix-assisted laser desorption/ionization bioreactive probes: a clinical application of mass spectrometry, J Am Soc Mass Spectrom 11(2) (2000), 172-175.
74. M. Toyota, C. Ho, N. Ahuja, K.W. Jair, Q. Li, M. Ohe-Toyota, S.B. Baylin and J.P. Issa, Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification, Cancer Res 59(10) (1999), 2307-2312.
75. F. Turecek, Mass spectrometry in coupling with affinity capture-release and isotope-coded affinity tags for quantitative protein analysis, J Mass Spectrom 37(1) (2002), 1-14.
76. O. Tureci, U. Sahin and M. Pfreundschuh, Serological analysis of human tumor antigens: molecular definition and implications, Mol Med Today 3 (1997), 342-349.
77. V.E. Velculescu, L. Zhang, B. Vogelstein and K.W. Kinzler, Serial analysis of gene expression, Science 270 (1995), 484-487.
78. A.K. Virmani, C. Muller, A. Rathi, S. Zoechbauer-Mueller, M. Mathis and A.F. Gazdar, Aberrant methylation during cervical carcinogenesis, Clin Cancer Res 7 (2001), 584-589.
79. K. Wang, L. Gan, E. Jeffrey, M. Gayle, A.M. Gown, M. Skelly, P.S. Nelson, W. Ng, M. Schummer, L. Hood and J. Mulligan, Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray, Gene 229 (1999), 101-108.
80. T. Wang, D. Hopkins, C. Schmidt, S. Silva, R. Houghton, H. Takita, E. Repasky and S.G. Reed, Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis, Oncogene 19 (2000), 1519-1528.
81. J.B. Welsh, P.P. Zarrinkar, L.M. Sapinoso, S.G. Kern, C.A. Behling, B.J. Monk, D.J. Lockhart, R.A. Burger and G.M. Hampton, Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer, Proc Natl Acad Sci USA 98 (2001), 1176-1181.
82. I.H. Wong, Y.M. Lo, J. Zhang, C.T. Liew, M.H. Ng, N. Wong, P.B. Lai, W.Y. Lau, N.M. Hjelm and P.J. Johnson, Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients, Cancer Res 59 (1999), 71-73.
83. X.C. Xu, M.F. Mitchell, E. Silva, A. Jetten and R. Lotan, Decreased expression of retinoic acid receptors, transforming growth factor beta, involucrin, and cornifin in cervical intraepithelial neoplasia, Clin Cancer Res 5 (1999), 1503-1508.
84. J.R. Yates, 3rd., Mass spectrometry and the age of the proteome, J Mass Spectrom 33(1) (1998), 1-19.
85. L. Zhang, W. Zhou, V.E. Velculescu, S.E. Kern, R.H. Hruban, S.R. Hamilton, B. Vogelstein and K.W. Kinzler, Gene expression profiles in normal and cancer cells, Science 276 (1997), 1268-1272.